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Abstract
Thimerosal is a preservative used widely in vaccine formulations to prevent bacterial and fungal contamination in multidose
vials of vaccine. Thimerosal was included in the multidose non-adjuvanted pandemic 2009 H1N1 vaccine Panenza. In the
context of the analysis of the ex-vivo T cell responses directed against influenza vaccine, we discovered the in vitro toxicity
Panenza, due to its content in thimerosal. Because thimerosal may skew the immune response to vaccines, we investigated
in detail the ex-vivo effects of thimerosal on the fate and functions of T cells in response to TCR ligation. We report that ex-
vivo exposure of quiescent or TCR-activated primary human T cells to thimerosal induced a dose-dependent apoptotic cell
death associated with depolarization of mitochondrial membrane, generation of reactive oxygen species, cytochrome c
release from the mitochondria and caspase-3 activation. Moreover, exposure to non-toxic concentrations of thimerosal
induced cell cycle arrest in G0/G1 phase of TCR-activated T cells, and inhibition of the release of proinflammatory cytokines
such as IFN gamma, IL-1 beta, TNF alpha, IL-2, as well as the chemokine MCP1. No shift towards Th2 or Th17 cells was
detected. Overall these results underline the proapoptotic effect of thimerosal on primary human lymphocytes at
concentrations 100 times less to those contained in the multidose vaccine, and they reveal the inhibitory effect of this
preservative on T-cell proliferation and functions at nanomolar concentrations.
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Introduction
Thimerosal is a preservative used widely in vaccine formulations
to prevent bacterial and fungal contamination in multidose vials of
vaccine [1] [2]. Thimerosal, named also thiomersal or merthiolate
in clinical studies, is an ethylmercury-containing pharmaceutical
compound that contains 49.6% mercury by weight and metab-
olizes into ethylymercury (etHg) and thiosalicylate [3]. Thimerosal
has served as a preservative in vaccines since 1930, but in the late
1990 concerns came as more thimerosal-containing vaccines were
added to the recommended infant and child immunization
schedule [4]. Research on the specific in vivo toxicity of low doses
of etHg relevant to vaccines has only recently been performed [5]
[6,7]. In vitro, thimerosal has been shown to cause a number of
neurotoxic changes, including neuronal mitochondrial cell death
characterized by the release of cytochrome c and apoptosis
inducing factor from mitochondria to cytosol [8], DNA breaks and
caspase 3 activation in cultured human neuronal cells [9], and
mitochondrial-mediated apoptosis in a human neuroblastoma cell
line following exposure to mM concentrations of thimerosal [10].
The deleterious effects of thimerosal were also reported on HeLa S
epithelial cells, inducing an oxidative stress and cell death that
were completely suppressed by pretreating the cells with N-acetyl-
l-cysteine (NAC), a radical scavenger [11]. Thimerosal could also
cause S phase arrest followed by mitochondrial apoptosis in
murine myoblast cells that occurred via inhibition of the PI3K/
Akt/survivin signaling pathway [12]. Surprisingly, little is known
about the impact of thimerosal on immune cell functions.
Trompezinski et al. found that it induced an oxidative stress in
monocyte-derived dendritic cells [13], and Agrawal et al. reported
that thimerosal could exercise a Th2 promoting effect through
modulation of functions of dendritic cells [14]. At the T cell level,
thimerosal was reported to induce caspase-dependent mitochon-
drial apoptosis in the human leukemic Jurkat T cells [15,16].
In the context of the clinical trial MICIVAX, designed to
compare the efficacy and safety of influenza vaccine in patients
with inflammatory bowel disease (IBD) receiving immunosuppres-
sive therapy with patients not receiving immunosuppressants, we
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monitored the ex-vivo T cell response directed against the multidose
non-adjuvanted pandemic 2009 H1N1 vaccine Panenza. We
found that Panenza was toxic when used ex-vivo on patients’
peripheral blood lymphocytes (PBMC) in T-cell assays, and this
multidose vaccine-related toxicity was attributed to the preserva-
tive thimerosal. Because thimerosal may skew the immune
response to vaccines, we investigated in detail the ex-vivo effects
of thimerosal on the fate and functions of T cells in response to
TCR ligation.
Material and Methods
Vaccines and Antigens
All the following vaccines, except Pandemrix, were obtained
from Sanofi-Pasteur MSD (Lyon, France). Mutagrip (0.5 ml/dose)
contains Hemagglutinin (HA) and Neuraminidase (N) proteins
from the following three influenza strains (A/Brisbane/59/2007
[H1N1]-like, A/Brisbane/10/2007 [H3N2], B/Brisbane/60/
2008-like). Each dose includes 15 mg of the various HA proteins
but no thimerosal. Panenza, in its multidose format (10 doses),
contains for each dose 15 mg of HA derived from the A/
California/7/2009 [H1N1]- like strain and 45 mg of thimerosal.
Pandemrix from GlaxoSmithKline (Marly-le-Roi, France)
contains for each dose 3.5 mg of HA derived from the A/
California/7/2009 [H1N1]-like strain, the AS03 adjuvant and
5 mg of thimerosal.
PepTivator-CMV pp65, PepTivator-CMV IE1, PepTivator-
EBV EBNA-1 and PepTivator-EBV BZLF (Miltenyi Biotec SAS,
Paris, France) were used at 0.25 mg/ml, EBV, Tetanus toxoid
(TT) and tuberculin PPD (Statens Serum Institut, Copenhagen,
Denmark) were used at 5 mg/ml. As positive control, PBMC were
stimulated with plate-bound anti-CD3 (1 mg/ml) and anti-CD28-
mAbs (2 mg/ml) (Miltenyi Biotec SAS, Paris, France) during 1 to 3
days, according to the experiments.
Thimerosal was purchased from Sigma-Aldrich (St Quentin-
Fallavier, France) and diluted in sterile water to obtain a 1 g/ml
stock solution.
Study Design
Human peripheral blood mononuclear cells (PBMCs) were
isolated from heparinized blood of healthy adult donors (HD)
provided by the Etablissement Franc¸ais du Sang (EFS, Paris) in the
setting of EFS-Institut Pasteur convention, or from subjects
vaccinated with Mutagrip or Panenza. Some of these subjects
were enrolled in the clinical trial MICIVAX. The study was
approved under the authorization number 2704 by the ‘‘Ile-de
France III’’ Ethics Committee, Hoˆpital Tarnier-Cochin, Paris,
France. It was designed to detect T cell responses directed against
seasonal and pandemic influenza 2009 H1N1 vaccine in subjects
with inflammatory bowel disease. All the donors gave written
informed consent for samples to be used in this study, and all
samples and data were anonymized.
Flow Cytometry Assays
Membrane staining. The following conjugated monoclonal
antibodies (mAbs) were used: anti-CD3(SK7)-FITC, –PE or -APC,
anti-CD4(SK3)-FITC or –PerCP, anti-CD8(SK1)-FITC or –
PerCP, anti-CD19(SJ25C1)-PE, anti-CD14(M5E2)-FITC, anti-
CD56(NCAM16.2)-APC, anti-CD16(3G8)-FITC, all purchased
from Becton Dickinson (Le Pont de Claix, France). Cells were
stained for surface markers (at 4uC in the dark for 30 min) using
mixtures of mAbs diluted in PBS containing 0.5% BSA and 0.01%
NaN3 (PBA). Appropriate isotype control mAbs were used for
each staining combination. Samples were acquired on a
FACSCalibur (BD) flow cytometer using BD Cell Quest ProTM
software, and analyzed using FlowJo Software (Tree Star, Inc).
CFSE staining. PBMC were stained with 1 mM carboxy-
fluorescein succinimidyl ester (CFSE) (CellTrace cell prolife´ration
kit; Molecular Probes/Invitrogen) in PBS for 8 min at 37uC at a
concentration of 107 cells/ml. The labeling was stopped by
washing the cells twice with RPMI 1640 culture medium
containing 10% FBS. The cells were then resuspended at the
desired concentration and subsequently used for proliferation
assays, as previously reported [17].
Apoptosis assay using 7-AAD (7-amino-actinomycin D)
staining. Apoptosis of unstimulated or stimulated PBMCs,
CFSE-labeled or unlabeled, was determined using the 7-AAD
assay, as we previously reported [18] [19]. Briefly, cultured cells
were stained with 20 mg/ml nuclear dye 7-AAD (Sigma-Aldrich)
for 30 min at 4uC, washed in PBA and fixed in PBA 1% PFA.
Samples were acquired on a FACSCalibur (BD) flow cytometer
using Summit software (Beckman Coulter), and analyzed using
FlowJo Software. FSC/7-AAD dot plots distinguish living (FSChigh/
7-AADneg) from apoptotic (FSChigh/7-AAD+) cells, apoptotic bodies
(FSClow/7-AAD+) and debris (FSClow/7-AADneg).
Cell cycle analysis. The impact of thimerosal on cell cycling
was determined with the combined staining with BrdU and 7-AAD
(BD Pharmingen BrdU flow kit) that permits the enumeration and
characterization of cells that are actively synthesizing DNA (BrdU
incorporation) in terms of their cell cycle position (ie, G0/1, S, or
G2/M phase) defined by 7-AAD staining intensities. Staining was
performed according to the manufacturer’s recommendations.
DYm analysis. Variations of the mitochondrial transmem-
brane potential DYm during thimerosal-induced T-lymphocyte
apoptosis were studied using 3,39-dihexyloxacarbocyanine iodide
(DiOC6(3), Invitrogen). This cyanine dye accumulates in the
mitochondrial matrix under the influence of the DYm. Staining
conditions were previously described [20]. Briefly, 2.5 105
stimulated PBMCs were incubated in 100 ml of PBS containing
0.1 mM of DiOC6(3) for 30 min. DiOC6(3) membrane potential-
related fluorescence was recorded using FL1 PMT.
ROS detection. Oxidative stress was measured using hydro-
ethidine (HE) (Invitrogen), which is a reduced form of ethidium
bromide (EB) [21]. HE is non-fluorescent in its non-oxidized form,
and it is fully permeable to the cellular membrane, thus permitting
its entrance into the cytoplasm, where it competes for the available
oxidants. Once HE is oxidized, fluorescent EB is trapped inside
the nucleus where it intercalates into DNA. PBMCs were
stimulated overnight with soluble anti-CD3 mAbs (1 mg/ml) in
the presence of thimerosal at 3 mg/ml. In some experiments the
anti-oxidant N-acetylcysteine (NAC) (2.5 mM) was added to the
culture. Stimulated cells were co-stained with anti-CD4 mAbs,
DiOC6(3) (0.1 mM) and HE (1 mM) [22] [23] and analyzed on a
FACSCalibur (BD) flow cytometer.
Functional Assays
T-cell proliferation. T-cell proliferation was assessed by 3H-
thymidine incorporation or CFSE dilution assays. For 3H-
thymidine incorporation assay, PBMCs were resuspended in
culture medium (RPMI-1640 containing 2 mM L-glutamine,
20 mM Hepes, and 10 mg/ml penicillin/streptomycin) at an
initial concentration of 56105 cells/200 ml per well in 96-well flat
bottom plates and incubated for 5 days in the presence of the
indicated antigens or vaccines. In some experiments, the plates
were coated overnight at 4uC with the indicated concentrations of
Panenza and washed before adding PBMCs. Cultures cells were
pulsed with 1 mCi per well of [3H] thymidine (Amersham) over
the final 16 h of culture. Cells were harvested on a semi-
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automated 96-well plate harvester (Skatron), and the amount of
[3H]-thymidine incorporated was determined by liquid scintilla-
tion spectroscopy (Top count NXTTM, Perkin Elmer) and
expressed as cpm. In all experiments, measurements were effected
on at least triplicate samples. For CFSE dilution assay, at coculture
completion, CD3/CD28-stimulated CFSE-labeled T cells were
harvested, costained with anti-CD4 mAb and 7-AAD, and the
percentage of proliferating cells (defined as CFSElow fraction) in
gated CD4+ 7-AADneg cells was determined by flow cytometry.
MTT cell growth assay. PBMC stimulated with CD3/
CD28 mAbs, in the presence or absence of indicated concentrations
of thimerosal (0.18-3 mg/ml), either overnight or in kinetics
experiments, were tested for cell growth with the MTT assay kit
(Millipore SAS, Molsheim, France). Absorbance was read at 570 nm.
Cytokine and chemokine quantification. Cytokines and
chemokines were quantified in culture supernatants by multi-
analyte profiling (MAP) with Bio-Plex array system (Human
cytokine, chemokine and growth factor assay; Biorad Life Science,
Marnes-la-coquette, France), following the manufacturer’s instruc-
tions. In brief, 50 mL of supernatant were incubated with
antibody-linked magnetic beads for 2 h, washed twice, and
incubated for 1 h with biotinylated secondary antibodies. A final
incubation step of 30 min with streptavidin-phycoerythrin (PE)
preceded acquisition on the Luminex 100IS.
Immunoblot analysis
Immunoblots were performed as previously described [24].
Total cellular proteins were extracted in 250 mM NaCl-contain-
ing lysis buffer [250 mM NaCl; 0,1% NP40; 5 mM EDTA;
10 mM Na3VO4; 10 mM NaF, 5 mM DTT; 3 mM Na4P2O7 and
the protease inhibitor cocktail (EDTA-free protease inhibitor
tablets, Roche)]. 20 to 50 mg of protein extracts were run on 12%
SDS-PAGE and transferred at 4uC onto a nitrocellulose mem-
brane. After blocking, membranes were incubated with the
primary antibody (cleaved caspase-3 rabbit antibody, Asp175,
Cell signaling Technology, Inc) at room temperature overnight.
Horseradish peroxidase-conjugated secondary anti-rabbit antibod-
ies (Southern Biotech) were then incubated for 1 h and revealed
with the enhanced ECL detection system.
Confocal Microscopy analysis
PBMCs were incubated overnight either in medium, or with
thimerosal (0.9 mg/ml or 3 mg/ml) or staurosporine (1 mg/ml).
Cells were washed in PBS, fixed on poly-L-lysine coated slides
(Biovalley SA, Marnes La Coquette, France), permeabilized and
stained intracellularly with purified mouse anti-human cyto-
chrome c antibody (6H2.B4, BD Pharmingen) diluted in PBA
containing 0.01% saponin (Sigma Aldrich). The second-step
reagent was Alexa Fluor 488 anti-mouse IgG (Invitrogen).
The nuclei were stained with DAPI nucleic acid stain
(Invitrogen). The images were taken on a Leica SP5 from the
Institut Pasteur Imagopole facility.
Statistical Analyses
Parametric paired-samples Student’s t-test and the ANOVA test
were used to compare variables. P value ,0.05 were considered
statistically significant for all results.
Results
Dose-dependent Toxicity of Panenza on Memory T cells
specific for influenza vaccine
Patients with IBD enrolled in the clinical trial MICIVAX were
all vaccinated with the seasonal vaccine Mutagrip, and some of
them received 21 days later the adjuvanted pandemic 2009 H1N1
vaccine (Pandemrix) or the non-adjuvanted pandemic 2009 H1N1
vaccine Panenza. PBMC from these patients were stimulated in
vitro with various concentrations of Mutagrip or Panenza, and T-
cell proliferation was analyzed at day 5. In parallel, the T-cell
responses induced by persistent viruses, such as EBV and CMV, or
vaccine antigens, such as TT and PPD, were analyzed on the same
samples.
Figure 1A shows data from three patients. On the left panel, the
proliferative response to Mutagrip at day 21 post-vaccination was
detected at a wide range of concentrations (10 to 500 ng/
ml)(vaccine concentration is expressed as the final concentration of
HA) with a plateau reached at the concentration of 60 ng/ml. On
the middle panel, PBMC from the same patients at day 21 post-
vaccination with Panenza showed a dramatically different dose-
response to this vaccine that decreased as Panenza concentration
was increasing. On the right panel, the proliferative response of
these patients to persistent viruses i.e. CMV and EBV, and vaccine
antigens i.e. TT and PPD indicates that T cells from these patients
were able to exhibit a memory response to recall antigens. This
inhibitory effect of Panenza was also observed on PBMC from
vaccinated healthy donors. It was therefore independent of the
health condition of the donor. The inverse dose response curve to
Panenza was suggestive of an in vitro toxic effect of the vaccine.
To address this question, we compared the response obtained with
soluble vs coated Panenza, the coating allowing attachment of
vaccine proteins to the wells while eliminating non-protein
molecules. Figure 1B shows data from another representative
patient 21 days post-vaccination with the pandemic vaccine: a very
significant memory response was detected when plates were coated
with various concentrations of Panenza, reaching a plateau at
130 ng/ml, while soluble Panenza failed to induce this response.
We then addressed the question of Panenza toxicity on primary
lymphocytes using multiparametric flow cytometry including 7-
AAD as a marker of cell death, as we previously described [19].
Overnight incubation of PBMC from a healthy donor with
Panenza at 250 ng/ml induced the death of 99% of T cells,
whereas the death rate induced by Mutagrip was the same as that
of control cultures (21 to 23%) (Figure 1C). The toxicity of
Panenza was not restricted to CD4+ and CD8+ T cells, as it
affected all lymphocyte subsets, including B cells, NK cells, and
monocytes, and it was detected at very low concentrations of
Panenza (from 10 ng/ml) (Figure 1D). Under the same experi-
mental conditions, Mutagrip had no toxic effect on any of these
subsets (Figure 1C, 1D).
Thimerosal is responsible for Panenza toxicity on primary
T cells, and it induces mitochondrial permeability
transition and caspase activation.
The two vaccines Mutagrip and Panenza contain 15mg of HA
and NA proteins per dose, and the only difference between both is
the presence of the thimerosal preservative in Panenza (45mg/dose
of 0.5 ml i.e. final concentration 90 mg/ml). In order to determine
the origin of the toxicity of Panenza, PBMC from a HD were
stimulated 18 hrs with anti-CD3/CD28 mAbs in the presence of
0.18 to 3 mg/ml of thimerosal (equivalent dose of thimerosal
present in Panenza tested at 0.06 to 1 mg/ml). Figure 2A, left
panel, shows a dose-dependent toxicity of thimerosal, measured by
the MTT assay, which we observed in all the HD tested (more
than 20). The killing of TCR-stimulated T cells was very rapid,
occurring during the first 30 minutes (Figure 2A, right panel).
Thimerosal was also toxic on quiescent T cells, and the proportion
of apoptotic 7-AAD+CD3+ T cells following 18 hrs of treatment
increased in a dose-dependent manner, reaching 64% of CD3+ T
Thimerosal and Flu-Specific Cellular Response
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Figure 1. Dose-dependent Toxicity of Panenza on Memory T cells specific for influenza vaccine. A- PBMC from patients vaccinated with
the seasonal flu vaccine (Mutagrip) and the pandemic 2009 H1N1 vaccine (Pandemrix) were collected 21 days after vaccine administration. Cells
(56105 per well) were stimulated for 5 days with Mutagrip or the nonadjuvanted pandemic 2009 H1N1 Panenza vaccine at the indicated
concentrations (vaccine concentration is expressed as the final concentration of HA). Cells were also stimulated with CMV or EBV peptides at 0.25 mg/
ml, tetanus toxoid (TT) or tuberculin PPD at 5 mg/ml. Cultures were pulsed with 1 mCi per well of [3H] thymidine over the final 16 h of culture and cell
proliferation expressed in cpm. All tests were done in triplicate and results show the mean values for three patients. The bars indicate the mean and
Thimerosal and Flu-Specific Cellular Response
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cells at 0.9 mg/ml of thimerosal (Figure 2B upper panel).
Staurosporine, a strong inducer of apoptosis in many cell types
was used as a positive control, and the levels of apoptosis induced
by thimerosal was comparable to that induced by staurosporine
(Figure 2B, upper panel).
To better characterize the type of cell death induced by
thimerosal on primary T cells, we used the probe DiOC6(3), which
allows to study variations in the mitochondrial transmembrane
potential DYm during intrinsic cell death. This cyanine dye
accumulates in the mitochondria matrix under the influence of
DYm [25]. As shown in Figure 2B lower panel, T-cell apoptosis
induced by 18-hr incubation with thimerosal was associated with a
drop in DYm in CD3
+CD4+ T cells, which was observed
exclusively in 7-AAD+ T cells. As a positive control, staurosporine
also induced DYm disruption in CD3
+CD4+T cells, in agreement
with previous studies in human PBL [26] or in Hela cells [27]. The
involvement of the mitochondrial pathway in thimerosal induced
T-cell death was also observed when T cells were stimulated
through the TCR. The impact of thimerosal on the transition
states from living cells with intact DYm (DIOC6
high 7-AADneg) to
still living cells with a drop in DYm (7-AAD
neg DIOC6
low cells) to
dead cells (DIOC6
low 7-AADhigh) is shown in a representative
experiment (Figure 2C).
In addition to the loss of DYm, overnight treatment of primary T
cells with thimerosal induced cytochrome c release from the
mitochondria, as shown by confocal microscopy (Figure 3A). The
labeled cytochrome c was restricted to mitochondria in control
cells incubated in medium, while a more diffuse labeling dispersed
in the cytoplasm was observed in the presence of 0.9 mg/ml of
thimerosal. In cells treated with 3 mg/ml of thimerosal, cyto-
chrome c was washed out from the cells after its release and no
more labeled cytochrome c was detected. Same picture was seen in
staurosporine-treated cells (Figure 3A). The nuclei were condensed
but showed a strange jagged morphology following the treatment
with 3 mg/ml of thimerosal, while they were fragmented after
staurosporine treatment (Figure 3A).
The biochemical manifestations of the induction of the
mitochondrial permeability transition (MPT) were associated with
caspase-3 activation. This was observed whether T cells were
unstimulated (Figure 3B) or stimulated with anti-CD3 mAbs
(Figure 3C). Western blot analysis showed that thimerosal
activated caspase -3 in both unstimulated and TCR-triggered T
cells in a concentration-dependent manner. To confirm the role of
caspase activation in thimerosal-induced apoptosis, the broad
caspase inhibitor QVD [28] was used. T cells were treated with
QVD (5mM) and thimerosal (from 300 to 900 ng/ml) overnight.
Figure 3 B, C show that QVD prevented activation of caspase-3
induced by increasing doses of thimerosal, and this was associated
with the prevention of T-cell apoptosis. Similar data were obtained
when unstimulated or stimulated T cells were treated with
staurosporine (Figure 3B, C). These results indicate that induction
of MPT and cleavage activation of caspase-3 might play an
important role in apoptosis induced by thimerosal in human
primary T cells, either non activated or activated following TCR
ligation.
Inhibition of ROS prevents thimerosal-induced apoptosis
of TCR-stimulated T cells
We then addressed the question of the possible involvement of
oxidative stress in thimerosal-induced apoptosis, since a temporal
association between mitochondrial membrane permeabilization
and ROS production was reported in several cell types such as
primary thymocytes or tumor cells [22,29] [30]. We used HE to
detect cells with an increased oxidizing ability that we combined
with DiOC6s to make the link between thimerosal-induced DYm
disruption and oxidative stress. Figure 4A shows that thimerosal at
3 mg/ml induced a high production of ROS in anti-CD3-activated
T cells, and all HE+ cells showed a drop in DYm. To confirm the
role of ROS in thimerosal-induced apoptosis, the antioxidant
NAC was added together with thimerosal at the initiation of the
overnight stimulation of PBMC with anti-CD3 mAbs. As shown in
Fig 4A,B the inhibition of ROS levels by NAC prevented DYm
disruption and remarkably inhibited the proapoptotic effect of
thimerosal in both CD4+ and CD4- T cells. This protective effect
of NAC was observed whether T cells were stimulated by anti-
CD3 mAbs or unstimulated. Besides, NAC decreased the level of
cleavage activation of caspase-3 after exposure of CD3-stimulated
T cells to different doses of thimerosal, as shown in Figure 3C.
NAC had a similar effect on staurosporine-induced caspase-3
activation (Figure 3C).
Non-toxic concentrations of thimerosal significantly
inhibit the proliferation of T cells following TCR ligation,
resulting in G0/G1 phase arrest
The effect of thimerosal at non-toxic concentrations on the
proliferation of T cells in response to CD3/CD28 ligation was
determined. To quantitatively analyze the proliferation and
apoptosis of primary T cells ex-vivo, we labeled PBMC with CFSE,
a fluorochrome whose per cell fluorescent intensity halves with
each round of cell proliferation [31]. After 4 days of stimulation
with CD3/CD28 mAbs, cells were stained with CD4-specific
antibodies and 7-AAD. Figure 5A shows in a representative
experiment that thimerosal treatment at 180 ng/ml resulted in
inhibition of cell proliferation by more than 50% in both CD4+
and CD42 T cells, as evidenced by the drop in the percentage of
CFSElow cells (a reduction of 64% in control cultures to 25% in
cultures with thimerosal). This inhibition of cell proliferation was
not associated with activation-induced cell death, as shown by the
dot plots combining 7-AAD/CFSE staining in gated CD4+ cells
(Figure 5A). Indeed, 25% of CD4+CFSElow cells were 7-AAD+ in
CD3/CD28 stimulated control cultures compared to 23% in
cultures containing thimerosal at 180 ng/ml (Fig 5A). Figure 5B
shows a synthesis of the data obtained with 7 donors, indicating
standard deviation. Asterisks indicate significant P-values (p = 0.03) for comparison of cultures stimulated with Panenza at 0.02 to 0.5 mg/ml to
cultures stimulated with 0.01 mg/ml of Panenza (ANOVA test). B- PBMC from Pandemrix vaccinated patients were incubated with soluble Panenza at
indicated concentrations, or added to plates coated overnight at 4uC with indicated concentrations of Panenza. H3TdR (1mCi/well) was added at day 4
and T-cell proliferation was assessed at day 5. The bars indicate the mean and standard deviation. Asterisks indicate significant P-values (* ,0.05, **
,0.01, ***,0.001) for comparison of cultures stimulated with coated Panenza to cultures stimulated with soluble Panenza. C- PBMC from a patient
vaccinated with Mutagrip and then with Pandemrix were incubated overnight with culture medium, Mutagrip or Panenza at 0.25 mg/ml and the
percentage of apoptotic cells was determined by flow cytometry combining 7-AAD staining with CD3 and CD4 membrane detection. Dot plots
represent the co-expression of CD4 and 7-AAD on gated CD3+ T cells. D- PBMC from a patient vaccinated with Mutagrip and Panenza were incubated
overnight with either vaccine at various concentrations and the percentage of apoptotic (7-AAD+) cells within indicated subsets was determined
combining 7-AAD staining with CD19, CD3, CD8, CD4, CD56, CD16 or CD14. B cells were CD32CD19+, T cells were CD3+CD8+ or CD3+ CD4+, NK cells
were CD32CD56+CD16+, monocytes were CD32CD192CD14+.
doi:10.1371/journal.pone.0092705.g001
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Figure 2. Toxicity of thimerosal on TCR-activated T cells through alterations in mitochondrial membrane potential. A- Left panel:
PBMC from a HD were stimulated overnight with anti-CD3/CD28 mAbs in the presence or absence of thimerosal at indicated concentrations. Cell
viability was assessed using the MTT assay. Right panel: Kinetics of thimerosal effect on the viability of PBMC from a HD activated overnight with anti-
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that exposure to thimerosal decreases the percentage of living
proliferating cells (CFSElow/7-AADneg cells) (middle panel) while it
does not increase the percentage of dead proliferating cells
(CFSElow/7-AAD+ cells) (right panel).
This inhibition of proliferation could thus be due to cell cycle
arrest. Using the BrdU assay, which combines BrdU incorporation
into newly synthesized DNA strands to the DNA dye 7-AAD, we
found that exposure to thimerosal resulted in the accumulation of
CD3/CD28 mAbs, assessed using the MTT assay. Cultures were done in triplicate and these data are representative of at least three experiments
performed with three different donors. The bars indicate the mean and standard deviation. Asterisks indicate significant p-values (** ,0.05, ***0.01,
ANOVA test) for comparison of cultures stimulated in the presence of thimerosal to cultures stimulated without thimerosal. B- Induction by
thimerosal of apoptotic cell death and drop in the mitochondrial transmembrane potential DYm in unstimulated PBMC incubated overnight with the
indicated concentrations of the agent. Staurosporine was used as a positive control. Apoptosis was measured with 7-AAD and variations in DYm were
assessed using the DiOC6(3) probe. Dot plots in the upper panel show the dose-dependent apoptotic cell death induced by thimerosal in CD3
+CD4+
and CD3+CD42 T cells, and dot plots in the lower panel show the evolution of DYm in association with cell death on gated CD3
+CD4+ T cells. C-
Evolution of DYm in association with cell death on gated CD4
+ T cells following overnight stimulation of PBMC with anti-CD3/CD28 mAbs in the
presence of thimerosal or staurosporine. The four transition states (A to D) from living cells with intact DYm (DIOC6
high 7-AADneg) to apoptotic cells
(DIOC6
low 7-AADhigh) are calculated from the dot plots and shown in pie charts. Data of one representative experiment among six are shown.
doi:10.1371/journal.pone.0092705.g002
Figure 3. Thimerosal induces cytochrome c release and caspase-3 activation. A- Confocal analysis of PBMC incubated 16 hours either in the
presence of thimerosal (0.9 or 3 mg/ml), or with staurosporine (1 mg/ml) as a positive control. Cells were processed for cytochrome c staining (green)
and co-stained with DAPI (blue) to detect nuclei modifications. B-C Western blot analysis of active caspase-3 expression in PBMC incubated for 16 h in
medium (unstimulated) (B) or stimulated with anti-CD3 mAbs (C). The impact of indicated concentrations of thimerosal or staurosporine on active
caspase-3 expression is shown, together with the influence of the broad caspase inhibitor QVD and the anti-oxidant NAC.
doi:10.1371/journal.pone.0092705.g003
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T cells in the G0/G1 phase of the cell cycle (Figure 5C and 5D).
Cell cycle analysis performed after 72-hour incubation of CD3/
CD28-stimulated PBMC with increasing concentrations of
thimerosal (180, 300 and 900 ng/ml) showed that T cell-
accumulation in the G0/G1 phase occurred in a dose-dependent
manner, and after exposure to 900 ng/ml of thimerosal, only 1%
of the cells were in S phase compared to 55% in stimulated control
cultures (Figure 5C and 5D). As already shown in CFSE
Figure 4. ROS induction by Thimerosal in TCR-activated T cells and anti-apoptotic effect of NAC. A- PBMC from a HD were stimulated
overnight with anti-CD3 mAbs in the presence of thimerosal at 3 mg/ml, and NAC (2.5 mM) was added in half of the cultures. ROS production was
detected with HE, DYm was assessed using the DiOC6(3) probe, and apoptosis was measured with 7-AAD. The dot plots show combined analysis of
DYm and apoptosis or DYm and ROS production on gated CD4
+ T cells, in a representative experiment out of three experiments performed with three
different HD. B- PBMC from a HD were either unstimulated (left panel) or stimulated overnight with anti-CD3 mAbs in the presence or absence of
thimerosal at 3 mg/ml (right panel). The anti-oxidant NAC (2.5 mM) was added in some cultures. The percentages of CD4+ and CD42 T cells with a
concomitant drop in DYm and increased oxidizing ability (DIOC6
high 7-AADneg) under the indicated culture conditions are shown. The bars indicate
the mean and standard deviation from 3 experiments with three different donors. Asterisks indicate significant P-values (** ,0.001, ***0.0001) for
comparison of cultures stimulated with thimerosal and NAC to cultures stimulated with thimerosal only.
doi:10.1371/journal.pone.0092705.g004
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Figure 5. Thimerosal inhibits T-cell proliferation and induces a G0/G1 cell cycle arrest. A- PBMC from a HD were labeled with CFSE and
stimulated during 4 days with anti-CD3/CD28 mAbs in the presence or not of thimerosal. At the end of the culture, cells were co-stained with anti-
CD4 mAbs and 7-AAD, and the rate of proliferation in CD4 T cells was determined (upper panel) combined with their priming for apoptosis (lower
panel). B- The experiment of panel A was performed with 7 different HD and the bars indicate the mean and standard deviation. The left panel shows
the percentage of total proliferating cells, the middle panel shows the proliferation of living cells and the right panel shows the proliferation of dying
cells. Asterisks indicate significant P-values (*,0.05, ANOVA test) for comparison of cultures stimulated in the presence of thimerosal at 180 ng/ml to
cultures stimulated in the absence of thimerosal. C: Cell cycle analysis of PBMC stimulated with anti-CD3/CD28 mAbs in the presence of thimerosal at
three different concentrations. The pie charts show the repartition of cells in the various phases of the cell cycle. D- Curves show the mean values
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experiments, cell cycle arrest was not associated with significant
increase in apoptotic cells (Figure 5C).
Impact of thimerosal on cytokine and chemokine release
upon TCR ligation
Fig 6 shows the pattern of cytokines and chemokines
simultaneously quantified by multiplex bead assay arrays in
supernatants from 16-hour stimulation with anti-CD3/
CD28 mAbs of freshly isolated PBMC from HD. High levels of
cytokines associated with general activation, such as IL-1b, TNF
alpha, IL-6 and IL-2 were detected following TCR ligation. As
expected, the Th1 cytokine IFN gamma was produced in high
amount whereas low levels of Th2 cytokines (IL-4, IL-5 or IL-13)
were detected. Cytokines involved in the promotion of Th17 such
as IL-9 and IL-17 were significantly produced, as well as the anti-
inflammatory cytokine IL-10. Finally, extremely high levels of the
chemokines MIP1-alpha, MIP1-beta, IP-10, MCP1, IL-8 and
RANTES were induced by CD3/CD28 ligation.
Following exposure to various concentrations of thimerosal (30,
300 and 3000 ng/ml), the release of the proinflammatory
cytokines IL-1b, TNF alpha, IL-2 and the Th1 cytokine IFN
gamma was reduced in a dose-dependent manner. The observa-
tion of the concomitant decrease in IL-1b and IFN gamma
production is consistent with the recent finding that IFN gamma
potentiates IL-1b release from human cells [32]. The levels of most
of the cytokines were under the threshold of detection after
exposure to Thimerosal 3mg/ml, which may be partly due to the
toxicity of the agent at this concentration. Exposure to thimerosal
did not induce the release of the Th2 cytokines IL-4 and IL-5, and
it slightly inhibited the production of IL-13, indicating that
thimerosal did not induce a Th1 to Th2 shift. Th17-related
cytokines were not affected, whereas an inhibition of IL-10
production was found. Among the chemokines released following
TCR ligation, MCP1 was the most susceptible to the suppressive
effect of thimerosal in a dose-dependent manner. It is noteworthy
that RANTES production was increased at the dose of 300 ng/ml
of thimerosal and it persisted at high level after exposure to 3 mg/
ml of the agent. Altogether, these data indicate that exposure of T
cells to non-toxic concentrations of thimerosal during their
activation through the TCR decreases the pro-inflammatory
response, including the production of IFN gamma essential in
mediating protective immunity to viral infections.
Discussion
This study was initiated when we discovered, in a proliferative
assay, the ex-vivo dose-dependent toxicity of the multidose non-
adjuvanted pandemic 2009 H1N1 vaccine Panenza on PBMC
from vaccinated people, while the seasonal influenza vaccine
Mutagrip was not toxic under the same conditions. Coating of
Panenza proteins on the plates before lymphocyte stimulation
enabled the detection of Flu-specific memory T cells, indicating
that the toxic molecule was not a protein. Comparison of
Mutagrip and Panenza composition revealed that thimerosal was
the only compound that differed between the two vaccines. As a
vaccine preservative, thimerosal is used in concentrations of
0.003% to 0.01%. [2]. A vaccine containing 0.01% thimerosal
contains 50 mg of thimerosal per 0.5 ml dose or approximately 25
micrograms of mercury per 0.5 ml dose. Panenza that we used in
our study contained 45 mg of thimerosal per 0.5 ml dose (90 mg/
ml). The toxic and immunomodulatory effects of thimerosal that
we report herein have been detected at the final concentration of
30 ng/ml to 3 mg/ml, i.e. 3000 to 30 times less concentrated than
in the vaccine. Therefore our results provide meaningful
information on the possible effects of the use of thimerosal on
vaccine-induced immunity. Our study showed that short-term
exposure to thimerosal at low concentrations could induce
mitochondrial apoptosis in TCR-activated primary human T cells
and could suppress Th1 polarization at non-toxic concentrations.
These observations suggest that thimerosal may alter in vivo
vaccine-induced immunity. Moreover, it was found to induce ex-
vivo false-positive results in the monitoring with Elispot technique
of the clinical efficacy of influenza vaccines, as we reported
recently[33].
Although thimerosal has been shown to promote apoptosis in
some cell types, they were all tumor cells [34]
[8,9,10,11,12,15,35,36] and this study is the first one to
demonstrate the proapoptotic effect of thimerosal on primary
human T cells. The dose-dependent toxic effect of thimerosal was
detected after a short-term (16 h) exposure to the agent in both
unstimulated and TCR-stimulated CD4 and CD8 T cells, but also
in other blood mononuclear subsets such as NK cells, monocytes
or B cells, indicating a broad effect of the agent on the effectors of
the immune system. In the first 3 hours of exposure to thimerosal
of primary lymphocytes from healthy donors, morphological
changes, including membrane alterations and cell shrinkage, were
observed, detected by the FSC/SSC parameters by flow cytom-
etry. Cell viability, assessed by the MTT assay, as well as the 7-
AAD flow cytometry assay, showed a time- and concentration-
dependent decrease in cell survival upon thimerosal exposure.
Mitochondria play a crucial role in regulating apoptosis [15] [37],
and it was found involved in thimerosal-induced cell death of
several tumor cell types [10] [9] [12] [11] [15]. To identify the
apoptotic pathway associated with thimerosal-mediated cell death
of primary lymphocytes, we used the probe DiOC6(3), which
allows to study variations in the mitochondrial transmembrane
potential DYm during intrinsic cell death [25]. We found that
thimerosal induced the loss of mitochondrial membrane potential
both in quiescent T cells and in TCR-activated T cells. This was
strongly associated with enhanced intracellular reactive oxygen
species (detected with HE), release of cytochrome c and caspase-3
activation. Interestingly, thimerosal toxicity was completely
prevented by the radical scavenger NAC. Altogether, these data
are consistent with previous observations made in other cell types,
such as Jurkat T cells where thimerosal triggered apoptosis via the
mitochondrial pathway by inducing oxidative stress and depletion
of GSH [15], and HeLa S epithelial cells in which thimerosal-
mediated toxic response was almost completely suppressed by
pretreating the cells with NAC [11].
We also report that Thimerosal was a potent inhibitor, at non-
toxic concentrations, of T-cell proliferation induced in a 3-day
culture by TCR ligation with anti-CD3/CD28 mAbs, as shown by
the combined staining with CFSE/7-AAD. Cell cycle analysis
performed under these conditions with increasing concentrations
of thimerosal (180 to 900 ng/ml) revealed a dose-dependent
accumulation of T cells in G0/G1 phase, and after exposure to
900 ng/ml of thimerosal, only 1% of the cells were in S phase.
Woo et al reported that thimerosal induced G2/M phase arrest in
from 7 HD, demonstrating the accumulation of cells in G0/G1 phase and the disappearance of cells in the S phase after exposure to increasing
concentrations of thimerosal. Asterisks indicate significant P-values (** ,0.01, ***0.001) for comparison of the proportions of cells in G0/G1 or in S
phase with or without thimerosal.
doi:10.1371/journal.pone.0092705.g005
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human leukemic cells [36] and Li et al reported that thimerosal
induced S phase arrest in C2C12 myoblast cells [12]. Our study is
the first to report that thimerosal induces a G0/G1 arrest. This
suggests that thimerosal may cause cell cycle arrest by different
mechanisms in different cell types, and that thimerosal may
interfere with TCR-dependent T-cell activation at low and non-
toxic concentrations.
Figure 6. Impact of thimerosal on cytokine and chemokine release upon TCR ligation. Pattern of cytokines and chemokines
simultaneously quantified by multiplex bead assay arrays in supernatants from freshly isolated PBMC following 16-hour stimulation with anti-CD3/
CD28 mAbs in the absence or presence of three different concentrations of thimerosal. The bars indicate the mean and standard deviation from
experiments with three different donors. Asterisks indicate significant P-values (* ,0.05, ANOVA test) for comparison with cultures without
thimerosal.
doi:10.1371/journal.pone.0092705.g006
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Although antibodies are the predominant protective correlates
in the case of vaccines, cell-mediated immune functions are critical
in protection against intracellular infections, and in almost all
diseases, CD4+ cells are necessary to help B cell development [38].
For example, McElhaney et al. [39] found that cytokine
production and proliferation of T cells in the presence of influenza
antigen correlated with protection of elderly adults. Thus, whereas
antibody production is critical in the young to prevent primary
influenza infection, CD4+ cells may be more important in
immunologically experienced individuals undergoing heterosubty-
pic infection. This was recently suggested in a study conducted in
healthy volunteers with no detectable antibodies to the challenge
viruses H3N2 or H1N1, demonstrating that preexisting CD4 T
cells responding to pandemic H1N1 internal proteins with
cytotoxic activity were associated with lower virus shedding and
less severe illness [40]. The authors suggested that these cells are
an important correlate of homotypic and heterotypic response that
may limit severity of influenza infection by new strains in the
absence of specific antibody response [40]. In another study,
higher frequency of preexisting IFN-c+IL-2- CD8+ T cells specific
to conserved core protein epitopes inversely correlated with
symptom score, and correlated with crossprotection against
influenza in the absence of crossreactive neutralizing antibodies
[41]. In this context, our observations of the ability of thimerosal to
inhibit T-cell proliferation in response to influenza vaccine
antigens are meaningful. In particular, we report that non-toxic
concentrations of this agent had an impact on the pattern of
mediators produced in response to CD3/CD28 mAbs, as thimer-
osal at 300 ng/ml inhibited the production by activated T cells of
the proinflammatory molecules IFN-c, IL-1b and TNF-a. The
Th1 cytokine IFN-c is critical for innate and adaptive immunity
against viral and intracellular bacterial infections. IFN-c contrib-
utes to macrophage activation by increasing phagocytosis and
priming the production of proinflammatory cytokines and potent
antimicrobials, it also controls the differentiation of naive CD4 T
cells into Th1 effectors, which mediate cellular immunity against
viral and intracellular pathogens [42]. Inhibition of IFN-c
production following exposure to thimerosal may be detrimental
for vaccine-specific immunity if this effect occurred in vivo, as
suggested by the essential role of T cells producing this cytokine in
protection against illness in influenza antibody naı¨ve individuals
[41]. Of note, thimerosal did not induce a shift to Th2 cytokine
production, in contrast to the finding of an earlier study[14].
However, the experimental conditions were different since a prior
‘‘priming’’ of mature DC with thimerosal was required for Th2
differentiation in DC-T cocultures[14].
In conclusion, our work indicates that ex-vivo exposure of
quiescent or TCR-activated primary human T cells to thimerosal
induces apoptosis associated with depolarization of mitochondrial
membrane, generation of reactive oxygen species, release of
cytochrome c from the mitochondria and caspase-3 activation.
Moreover, exposure to non-toxic concentrations of thimerosal
induces cell cycle arrest in G0/G1 phase and inhibition of the
release of proinflammatory cytokines, including IFN-c. Multi-dose
vials of vaccines containing thimerosal remain important for
vaccine delivery, in particular in the event of pandemics or health
emergencies. However, our observations regarding its ex-vivo
toxicity and immunomodulatory effects on human primary
lymphocytes highlight the need to use this preservative with
caution and avoid it if possible.
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